Clinical trials in neuro-oncology: One step forward, two steps back?

Current Opinion in Neurology

Volumn 24, Issue 6, 2011, Pages 597-598

  Weller, Michael ^a   Stupp, Roger ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CEDIRANIB; CILENGITIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; PEPTIDE VACCINE; PROTEIN P53; TALAMPANEL; TEMOZOLOMIDE; VASCULOTROPIN;

ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER TISSUE; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); EDITORIAL; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOGENICITY; INHIBITION KINETICS; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; UNSPECIFIED SIDE EFFECT;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; GLIOMA; HUMANS; MEDICAL ONCOLOGY; NEUROLOGY; PROSPECTIVE STUDIES; RESEARCH DESIGN;

EID: 81855194376     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32834c091e     Document Type: Editorial

References (15)

1. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765-773.
2. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010; 16:2443-2449.
3. Gilbert MR, Wang M, Aldape KD, et al. RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). ASCO Meeting Abstracts 2011; 29:2006.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996. (Pubitemid 40349501)
5. Wick W, Steinbach JP, Kuker WM, et al. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004; 62:2113-2115. (Pubitemid 38738235)
6. TolcherAW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88:1004-1011. (Pubitemid 36560766)
7. Aldape KD, Wang M, Sulman EP, et al. RTOG 0525: molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma. ASCO Meeting Abstr 2011; 29:LBA2000.
8. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28:2712-2718.
9. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008; 71:1372-1380.
10. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011; 29:142-148.
11. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733-4740.
12. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95. (Pubitemid 46075199)
13. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28:2817-2823.
14. Batchelor T, Mulholland P, Neyns B, et al. A phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients. Proc ESMO Ann Oncol Meeting Abstr 2010; 21:LBA7.
15. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28:4722-4729.